» Articles » PMID: 36204626

Gut Microbiome and Microbial Metabolites in NAFLD and After Bariatric Surgery: Correlation and Causality

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2022 Oct 7
PMID 36204626
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently related to a heavy socioeconomic burden and increased incidence. Since obesity is the most prevalent risk factor for NAFLD, weight loss is an effective therapeutic solution. Bariatric surgery (BS), which can achieve long-term weight loss, improves the overall health of patients with NAFLD. The two most common surgeries are the Roux-en-Y gastric bypass and sleeve gastrectomy. The gut-liver axis is the complex network of cross-talking between the gut, its microbiome, and the liver. The gut microbiome, involved in the homeostasis of the gut-liver axis, is believed to play a significant role in the pathogenesis of NAFLD and the metabolic improvement after BS. Alterations in the gut microbiome in NAFLD have been confirmed compared to that in healthy individuals. The mechanisms linking the gut microbiome to NAFLD have been proposed, including increased intestinal permeability, higher energy intake, and other pathophysiological alterations. Interestingly, several correlation studies suggested that the gut microbial signatures after BS become more similar to those of lean, healthy controls than that of patients with NAFLD. The resolution of NAFLD after BS is related to changes in the gut microbiome and its metabolites. However, confirming a causal link remains challenging. This review summarizes characteristics of the gut microbiome in patients with NAFLD before and after BS and accumulates existing evidence about the underlying mechanisms of the gut microbiome.

Citing Articles

sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.

Olotu T, Ferrell J Microorganisms. 2025; 12(12.

PMID: 39770690 PMC: 11728176. DOI: 10.3390/microorganisms12122488.


Metabolic dysfunction associated fatty liver disease in healthy weight individuals.

Mendez-Sanchez N, Brouwer W, Lammert F, Yilmaz Y Hepatol Int. 2024; 18(Suppl 2):884-896.

PMID: 39052203 PMC: 11449956. DOI: 10.1007/s12072-024-10662-w.


Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.

Rochon J, Kalinowski P, Szymanek-Majchrzak K, Grat M World J Gastroenterol. 2024; 30(23):2964-2980.

PMID: 38946874 PMC: 11212696. DOI: 10.3748/wjg.v30.i23.2964.


Distinct Gut Microbial Signature and Host Genetic Variants in Association with Liver Fibrosis Severity in Patients with MASLD.

Satthawiwat N, Jinato T, Sutheeworapong S, Tanpowpong N, Chuaypen N, Tangkijvanich P Nutrients. 2024; 16(12).

PMID: 38931155 PMC: 11206871. DOI: 10.3390/nu16121800.


The Reduced Gut Species Is Linked to Liver Enzyme Elevation and Insulin Resistance in Pediatric Fatty Liver Disease.

Tsai C, Chiu M, Kek H, Yang M, Su Y, Liu H Int J Mol Sci. 2024; 25(7).

PMID: 38612453 PMC: 11011648. DOI: 10.3390/ijms25073640.


References
1.
Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A . Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.e5. PMC: 5502730. DOI: 10.1016/j.cmet.2017.04.001. View

2.
Michail S, Lin M, Frey M, Fanter R, Paliy O, Hilbush B . Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015; 91(2):1-9. PMC: 4358749. DOI: 10.1093/femsec/fiu002. View

3.
Rahman K, Desai C, Iyer S, Thorn N, Kumar P, Liu Y . Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016; 151(4):733-746.e12. PMC: 5037035. DOI: 10.1053/j.gastro.2016.06.022. View

4.
Jansen P, van Werven J, Aarts E, Berends F, Janssen I, Stoker J . Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis. 2011; 29(1):48-51. DOI: 10.1159/000324128. View

5.
Lee C, Florea L, Sears C, Maruthur N, Potter J, Schweitzer M . Changes in Gut Microbiome after Bariatric Surgery Versus Medical Weight Loss in a Pilot Randomized Trial. Obes Surg. 2019; 29(10):3239-3245. DOI: 10.1007/s11695-019-03976-4. View